AM1476   Click here for help

GtoPdb Ligand ID: 13189

Compound class: Synthetic organic
Comment: AM1476 is a novel peripherally-acting serotonin 5‑HT2B receptor antagonist that was developed to reduce fibrosis-induced tissue damage and scarring. Example 49 in WO2016207231A1 represents the AM1476 racemate, and the hydrobromide formulation is example 50 [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 2
Topological polar surface area 85.7
Molecular weight 236.25
XLogP 0.97
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@@H]1CN(C(=N)N)N=C1C2=C(C=C(C=C2)F)O
Isomeric SMILES FC1=CC(=C(C=C1)C2=NN(C[C@H]2C)C(N)=N)O
InChI InChI=1S/C11H13FN4O/c1-6-5-16(11(13)14)15-10(6)8-3-2-7(12)4-9(8)17/h2-4,6,17H,5H2,1H3,(H3,13,14)/t6-/m1/s1
InChI Key AQXHIDRAVIMBME-ZCFIWIBFSA-N
No information available.
Summary of Clinical Use Click here for help
AM1476 is a clinical candidate. It has been granted EU (EMA) and US (FDA) orphan designations for the treatment of skin and lung manifestations of systemic sclerosis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04691115 Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects Phase 1 Interventional AnaMar AB